hotspot -WSS

hotspot

author：knowledge 2025-09-27 16:47:16 - browse：56

STAT's Damian Garde speaks with Mikael Dolsten and Mathai Mammen, in New York on March 21, 2024 — From left to right, STAT's Damian Garde; Mikael Dolsten, chief scientific officer of Pfizer research and development; and Rose Loughlin, Moderna’s senior vice president of early research and development, discuss the future of pharma at the STAT 2024 Breakthrough Summit East. STAT

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday.

“We used to say, well, you may spend five years in the research phase, another five in development. Now I see a project that takes one year of research, from an idea to studies,” said Mikael Dolsten, chief scientific officer and president of Pfizer research and development. “Time is life. You care about patients. And when the distance to run is long, it holds back the energy and the inspiration.”

Key to that success are transformative new technologies like messenger RNA, which powered vaccines developed by Pfizer with its partner BioNTech.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Shifting the focus from loneliness to social health

New study raises questions about niacin and heart health

MD Anderson's Padmanee Sharma responds to research credit suit

HIV drugs protect against transmission, even in unprotected sex

At ASCO, AstraZeneca reports strong data for breast cancer drug

focus

hotspot

focus

As demand for Covid shots wanes, Moderna seeks its next success

Researchers tackle phage therapy hurdles for wider adoption

In age of alternative facts, a scholarly course on calling out crap

New CMS data security rules will hurt Medicare, Medicaid research

Guidelines to prevent youth baseball injuries need more muscle

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Hollywood unions extend contract negotiations for actors

ASCO: AstraZeneca says CAR

Medical records are filled with copy

Hospitals are piloting generative AI tools as regulators play catch

leisure time

Weight loss drugs aren’t covered by Obamacare. That may change

As AI regulations shape up, health tech startups beg for clarity

WATCH: Why do our ears pop?

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Medicare Advantage enrollment grows 7.1% to 33.4 million people

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

entertainment

explore

focus

leisure time